



Clearbridge Health Limited
37 Jalan Pemimpin #08-05 Mapex Singapore 577177
TEL 65 6251 0136 FAX 65 6251 0132
clearbridgehealth.com

Clearbridge optimises capital structure with bank facilities to finance recent acquisitions

- *Believes optimal capital structure will pave the way for more EBITDA-focused acquisitions*

SINGAPORE – 15 May 2018 – Clearbridge Health Limited (“Clearbridge” or the “Company” and together with its subsidiaries, the “Group”) (明策集团), a healthcare company with a focus on the delivery of precision medicine in Asia, announced it has secured bank facilities of approximately S\$5.6 million to finance the two recently completed acquisitions namely Indonesia-based renal care services provider, PT Tirta Medika Jaya (“PT Tirta”) and Singapore-based medical and aesthetic services provider, Medic Surgery and Laser Clinic (“MSLC”).

Out of the total cash consideration for these two acquisitions, 40% was funded by the Company’s initial public offering proceeds and the balance by bank borrowings.

Mr Jeremy Yee (余斌), Executive Director and Chief Executive Officer of Clearbridge, said: *“We are financing these acquisitions in a way that we believe will optimise Clearbridge’s capital structure, which will in turn pave the way for our Group to continue the regional expansion of our medical clinics/centres business in a sustainable and prudent manner, with the clear aim of building shareholder value with more EBITDA-focused acquisitions.*

“Our recently announced first quarter results ended 31 March 2018, is a strong indication of the encouraging prospects of this business segment, which we had started only in July 2017. With the upcoming contribution from PT Tirta and MSLC, we expect further positive growth on the Group’s revenue and EBITDA in the current financial year.”

-- END --



Clearbridge Health Limited
37 Jalan Pemimpin #08-05 Mapex Singapore 577177
TEL 65 6251 0136 FAX 65 6251 0132
clearbridgehealth.com

About Clearbridge Health Limited

Clearbridge Health Limited is a healthcare company with a focus on the delivery of precision medicine in Asia. Its business comprises laboratory testing services, medical clinics/centres and strategic equity participation in complementary precision medical technology companies. Through the delivery of precision medicine in Asia, it seeks to empower clinicians and healthcare professionals to make more reliable and accurate diagnoses, provide insights to disease management, and tailor personalised prevention and timely treatment programmes for patients.

For more information, please visit us at www.clearbridgehealth.com.

Issued by and on behalf of Clearbridge Health Limited

August Consulting

Tel: +65 6733 8873

Silvia Heng, silviaheng@august.com.sg

Wrisney Tan, wrisneytan@august.com.sg

Zavier Ong, zavierong@august.com.sg

This press release has been prepared by the Company and its contents have been reviewed by the Company's sponsor, United Overseas Bank Limited (the "Sponsor"), for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited (the "SGX-ST").

The Sponsor has not independently verified the contents of this press release. This press release has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this press release, including the correctness of any of the statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Mr Chia Beng Kwan, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.